Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 04, 2023 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP Chief Patient & Ext Af Off | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,512 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 66,512 F1: Restricted stock unit award that vests on 03/31/2030. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 882 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 882 |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 6,637 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,637 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2018 Filed Jan 25, 2018 23:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,824 | $86.52 | $503,892.48 |
DisclosureSEC source: 0001209191-18-005468 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · derivative · entry 12 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 13,750 | $160.00 | $2,200,000.00 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,163 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F6 · balance_after: Reflects a change in the form of ownership resulting from transfers of shares between a trust and Mr. Sachdev. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 13,750 | $83.36 | $1,146,200.00 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,672 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · derivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,578 Underlying: Common Stock · 18,672 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/5/2014. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $159.35 | $111,545.00 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,163 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $159.35 (range $159.27 to $159.45). Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 13,312 | $158.59 | $2,111,150.08 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,863 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $158.59 (range $158.20 to $159.10). Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 18,410 | $157.67 | $2,902,704.70 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,175 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $157.67 (range $157.18 to $158.17). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 13,750 | $83.36 | $1,146,200.00 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 18,672 | $77.31 | $1,443,532.32 |
DisclosureSEC source: 0001209191-18-004928 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 83 | $147.29 | $12,225.07 |
DisclosureSEC source: 0001209191-17-061524 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,710 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $149.34 | $14,934.00 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,710 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $148.35 | $148,350.00 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,810 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $148.35 (range $148.19 to $148.70). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,200 | $147.70 | $324,940.00 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,810 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $147.70 (range $147.18 to $148.15). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,200 | $146.53 | $468,896.00 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,010 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $146.53 (range $146.16 to $147.14). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,438 | $145.26 | $1,806,743.88 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,210 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.93 to $145.87). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,362 | $144.47 | $2,508,288.14 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,648 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $144.47 (range $143.90 to $144.89). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,800 | $143.49 | $401,772.00 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,010 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $143.49 (range $142.87 to $143.85). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $142.40 | $128,160.00 |
DisclosureSEC source: 0001209191-17-058477 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,810 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $142.40 (range $141.83 to $142.70). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,564 | $162.07 | $253,477.48 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,710 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $162.07 (range $161.90 to $162.43). Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,461 | $161.44 | $720,183.84 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,274 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $161.44 (range $160.90 to $161.89) Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $160.04 | $80,020.00 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,735 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $160.04 (range $159.64 to $160.25). Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $158.90 | $206,570.00 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,235 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $158.90 (range $158.61 to $159.53). Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $158.05 | $126,440.00 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,535 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $158.05 (range $157.48 to $158.37). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · derivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 20,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20,000 | $161.00 | $3,220,000.00 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,335 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $77.31 | $1,546,200.00 |
DisclosureSEC source: 0001209191-17-046029 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,500 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-17-037926 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,500 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,500 | $125.00 | $3,812,500.00 |
DisclosureSEC source: 0001209191-17-037926 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,335 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,500 | $51.75 | $1,578,375.00 |
DisclosureSEC source: 0001209191-17-037926 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 116 | $114.37 | $13,266.92 |
DisclosureSEC source: 0001209191-17-033067 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,335 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,593 | $45.11 Strike: $45.11 | $1,289,830.23 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,593 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,032 | $48.74 Strike: $48.74 | $1,415,019.68 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · derivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,032 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,156 | $37.86 Strike: $37.86 | $649,526.16 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · derivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,156 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,719 | $38.80 Strike: $38.80 | $221,897.20 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · derivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,719 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 29,032 | $110.00 | $3,193,520.00 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,335 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 51,468 | $106.30 | $5,471,048.40 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,367 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 28,593 | $45.11 | $1,289,830.23 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 29,032 | $48.74 | $1,415,019.68 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 17,156 | $37.86 | $649,526.16 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,719 | $38.80 | $221,897.20 |
DisclosureSEC source: 0001209191-17-023841 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,684 | $87.68 | $673,733.12 |
DisclosureSEC source: 0001209191-17-011110 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,335 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $87.68 (range $87.30 to $88.18). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock · Derivative | 31,065 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-17-008386 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,065 Underlying: Common Stock · 31,065 shares Expires 2027-02-02 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 15,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008386 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,019 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,753 | $0.01 | $57.53 |
DisclosureSEC source: 0001209191-17-008386 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,849 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/02/2016 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2017. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 116 | $93.36 | $10,829.76 |
DisclosureSEC source: 0001209191-16-150880 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,096 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 16, 2016 Filed May 18, 2016 13:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 117 | $81.67 | $9,555.39 |
DisclosureSEC source: 0001209191-16-121117 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,096 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,266 | $92.79 | $117,472.14 |
DisclosureSEC source: 0001209191-16-095843 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,096 F2 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $92.79 (range $92.42 to $93.11). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $91.82 | $82,638.00 |
DisclosureSEC source: 0001209191-16-095843 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,362 F2 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $91.82 (range $91.37 to $92.26). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.